AGENUS INC
Close on Oct 19, 2026
- Market cap
- $255.47M
- P/E (TTM)
- –
- Dividend yield
- –
About Agenus
Biological Products, (No Diagnostic Substances), SIC 2836
Agenus Inc. operates as a commercial-stage and clinical biopharmaceutical company focused on clinical products, pre-commercial products, and clinical research services. The company provides specialized research and development manufacturing services, licenses proprietary intellectual property, and manages collaborative commercial agreements. Its primary operational activities encompass clinical product distribution, contract research, collaborative agreements, and named patient programs. Agenus engages with commercial customers and healthcare partners, including Incyte Corporation, Bristol Myers Squibb, Gilead Sciences, Betta Pharmaceuticals, and GlaxoSmithKline.
The company conducts its business and research operations across multiple international jurisdictions, with documented geographic activities in the United States, the United Kingdom, Switzerland, and Belgium. Its corporate headquarters and principal executive offices are located at 3 Forbes Road in Lexington, Massachusetts.
Summary of the business section of Agenus's latest annual report, written by StockData.
Company profile
Company
- Legal name
- AGENUS INC
- Founded
- 1994
- Headquarters
- Lexington, MA
- Address
- 3 Forbes Road 02421
- Phone
- (781) 674-4410
- Website
- agenusbio.com
- Employees
- 81, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- AGEN
- Exchange
- Nasdaq
- IPO date
- Feb 4, 2000
- Shares outstanding
- 45M, Aug 4, 2026
- Public float
- $135.40M, Jun 30, 2025
- Filer category
- Accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Apr 12, 2024; 1-for-6 reverse, Oct 3, 2011
- SEC CIK
- 1098972
- CUSIP
- 00847G804
- ISIN
- US00847G8042
- LEI
- 529900NDQQGU5H4UJK81
- EIN
- 06-1562417
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Garo H. Armen | See Remarks, Director | 402,406 |
| Jennifer Buell | See Remarks, Director | 19,738 |
| Steven J. O'Day | Chief Medical Officer | 57,116 |
| Austin Charette | Principal Accounting Officer | 9,115 |
| Christine M. Klaskin | PFO & PAO | 23,510 |
| Marco Tullio Marcucci | Director | 5,480 |
| Thomas L. Harrison | Director | 47,545 |
| Brian Corvese | Director | 92,085 |
| Susan B. Hirsch | Director | 118,725 |
| Timothy Wright | Director | 55,391 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Armen | $1.35M | $3.60M | $617.42K | $7 | – |
| FY2024 Dr. Armen | $4.15M | $2.88M | $926.89K | $3 | – |
| FY2023 Dr. Armen | $5.86M | -$1.54M | $1.07M | $20 | – |
| FY2022 Dr. Armen | $5.63M | -$1.67M | $969.69K | $59 | $111 |
| FY2021 Dr. Armen | $9.76M | $8.65M | $2.81M | $79 | $125 |
| FY2020 Dr. Armen | $5.64M | -$1.57M | $1.18M | $78 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of February 28, 2026, we had 81 employees, of whom 19 held Ph.D.”
Corporate history
Events identified from SEC filings